Insider Selling: Cytokinetics, Incorporated (NASDAQ:CYTK) CEO Sells $634,455.00 in Stock

Cytokinetics, Incorporated (NASDAQ:CYTK) CEO Robert I. Blum sold 11,500 shares of the company’s stock in a transaction dated Monday, August 12th. The stock was sold at an average price of $55.17, for a total transaction of $634,455.00. Following the completion of the sale, the chief executive officer now owns 399,412 shares in the company, valued at approximately $22,035,560.04. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Cytokinetics Trading Down 0.3 %

Shares of CYTK opened at $55.88 on Thursday. The firm has a fifty day simple moving average of $55.13 and a two-hundred day simple moving average of $63.23. The firm has a market cap of $5.86 billion, a PE ratio of -10.35 and a beta of 0.75. Cytokinetics, Incorporated has a 1-year low of $25.98 and a 1-year high of $110.25.

Cytokinetics (NASDAQ:CYTK) last posted its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($1.31) EPS for the quarter, missing analysts’ consensus estimates of ($1.06) by ($0.25). The company had revenue of $0.25 million during the quarter, compared to the consensus estimate of $7.61 million. The business’s revenue was down 71.3% compared to the same quarter last year. During the same period in the previous year, the business posted ($1.34) EPS. As a group, research analysts forecast that Cytokinetics, Incorporated will post -4.5 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms recently weighed in on CYTK. Bank of America cut their price target on Cytokinetics from $70.00 to $60.00 and set a “neutral” rating on the stock in a research note on Thursday, May 23rd. Truist Financial reduced their price target on Cytokinetics from $86.00 to $70.00 and set a “buy” rating for the company in a report on Wednesday, May 29th. Barclays dropped their price target on shares of Cytokinetics from $100.00 to $95.00 and set an “overweight” rating on the stock in a research note on Thursday, May 23rd. HC Wainwright restated a “buy” rating and set a $90.00 price objective on shares of Cytokinetics in a research note on Monday. Finally, The Goldman Sachs Group downgraded shares of Cytokinetics from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $85.00 to $60.00 in a research note on Tuesday. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and fourteen have assigned a buy rating to the stock. According to MarketBeat, Cytokinetics presently has a consensus rating of “Moderate Buy” and a consensus target price of $77.65.

Hedge Funds Weigh In On Cytokinetics

Institutional investors have recently made changes to their positions in the business. J.Safra Asset Management Corp increased its holdings in Cytokinetics by 642.3% during the second quarter. J.Safra Asset Management Corp now owns 527 shares of the biopharmaceutical company’s stock valued at $29,000 after buying an additional 456 shares during the last quarter. Fifth Third Bancorp increased its stake in shares of Cytokinetics by 94.1% in the 1st quarter. Fifth Third Bancorp now owns 656 shares of the biopharmaceutical company’s stock worth $46,000 after purchasing an additional 318 shares in the last quarter. EntryPoint Capital LLC bought a new position in Cytokinetics in the 1st quarter worth $74,000. GAMMA Investing LLC bought a new position in Cytokinetics in the 4th quarter worth $80,000. Finally, Bessemer Group Inc. grew its holdings in Cytokinetics by 25,100.0% during the first quarter. Bessemer Group Inc. now owns 1,260 shares of the biopharmaceutical company’s stock valued at $88,000 after purchasing an additional 1,255 shares during the period.

Cytokinetics Company Profile

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.